Ayala Pharmaceuticals holds a performance score of 17 on a scale of zero to a hundred. The firm shows a Beta (market volatility) of 27.82, which signifies a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Ayala Pharmaceuticals will likely underperform. Use Ayala Pharmaceuticals information ratio and the relationship between the value at risk and price action indicator , to analyze future returns on Ayala Pharmaceuticals.
Risk-Adjusted Performance
Solid
Weak
Strong
Compared to the overall equity markets, risk-adjusted returns on investments in Ayala Pharmaceuticals are ranked lower than 17 (%) of all global equities and portfolios over the last 90 days. In spite of comparatively fragile basic indicators, Ayala Pharmaceuticals unveiled solid returns over the last few months and may actually be approaching a breakup point. ...more
Quick Ratio
14.77
Fifty Two Week Low
1.5600
Fifty Two Week High
33.6000
Ayala
Ayala Pharmaceuticals Relative Risk vs. Return Landscape
If you would invest 5.10 in Ayala Pharmaceuticals on October 23, 2025 and sell it today you would earn a total of 19.90 from holding Ayala Pharmaceuticals or generate 390.2% return on investment over 90 days. Ayala Pharmaceuticals is currently generating 20.392% in daily expected returns and assumes 94.6338% risk (volatility on return distribution) over the 90 days horizon. In different words, most equities are less risky than Ayala, and most traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon.
Expected Return
Risk
Given the investment horizon of 90 days Ayala Pharmaceuticals is expected to generate 127.06 times more return on investment than the market. However, the company is 127.06 times more volatile than its market benchmark. It trades about 0.22 of its potential returns per unit of risk. The Dow Jones Industrial is currently generating roughly 0.11 per unit of risk.
Ayala Pharmaceuticals Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Ayala Pharmaceuticals' investment risk. Standard deviation is the most common way to measure market volatility of otc stocks, such as Ayala Pharmaceuticals, and traders can use it to determine the average amount a Ayala Pharmaceuticals' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.2155
High Returns
Best Equity
ADXS
Good Returns
Average Returns
Small Returns
Cash
Small Risk
Average Risk
High Risk
Huge Risk
Negative Returns
Based on monthly moving average Ayala Pharmaceuticals is performing at about 17% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Ayala Pharmaceuticals by adding it to a well-diversified portfolio.
Ayala Pharmaceuticals Fundamentals Growth
Ayala OTC Stock prices reflect investors' perceptions of the future prospects and financial health of Ayala Pharmaceuticals, and Ayala Pharmaceuticals fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Ayala OTC Stock performance.
Assessing Ayala Pharmaceuticals' fundamental ratios provides investors with valuable insights into Ayala Pharmaceuticals' financial health and overall profitability. This information is crucial for making informed investment decisions. A high ROA would indicate that the Ayala Pharmaceuticals is effectively leveraging its assets and equity to generate significant profits, making it an appealing investment. Conversely, low Return on Assets could signal underlying management issues in assets and equity, indicating a necessity for operational refinements. Please also refer to our technical analysis and fundamental analysis pages.
Advaxis, Inc., a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of proprietary Listeria monocytogenes technology antigen delivery products in the United States. Advaxis, Inc. was founded in 2002 and is based in Monmouth Junction, New Jersey. Advaxis operates under Biotechnology classification in the United States and is traded on OTC Exchange. It employs 14 people.
Things to note about Ayala Pharmaceuticals performance evaluation
Checking the ongoing alerts about Ayala Pharmaceuticals for important developments is a great way to find new opportunities for your next move. OTC Stock alerts and notifications screener for Ayala Pharmaceuticals help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.
Ayala Pharmaceuticals is way too risky over 90 days horizon
Ayala Pharmaceuticals has some characteristics of a very speculative penny stock
Ayala Pharmaceuticals appears to be risky and price may revert if volatility continues
The company reported the previous year's revenue of 250 K. Net Loss for the year was (16.24 M) with profit before overhead, payroll, taxes, and interest of 3.24 M.
Ayala Pharmaceuticals currently holds about 28.15 M in cash with (16.04 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 15.5, which can makes it an attractive takeover target, given it will continue generating positive cash flow.
Evaluating Ayala Pharmaceuticals' performance can involve analyzing a variety of financial metrics and factors. Some of the key considerations to evaluate Ayala Pharmaceuticals' otc stock performance include:
Analyzing Ayala Pharmaceuticals' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Ayala Pharmaceuticals' stock is overvalued or undervalued compared to its peers.
Examining Ayala Pharmaceuticals' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
Evaluating Ayala Pharmaceuticals' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Ayala Pharmaceuticals' management team can help you assess the OTC Stock's leadership.
Pay attention to analyst opinions and ratings of Ayala Pharmaceuticals' otc stock. These opinions can provide insight into Ayala Pharmaceuticals' potential for growth and whether the stock is currently undervalued or overvalued.
It's essential to remember that evaluating Ayala Pharmaceuticals' otc stock performance is not an exact science, and many factors can impact Ayala Pharmaceuticals' otc stock market price. Therefore, it's also important to diversify your portfolio and not rely solely on one company or stock for your investments.
Additional Tools for Ayala OTC Stock Analysis
When running Ayala Pharmaceuticals' price analysis, check to measure Ayala Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Ayala Pharmaceuticals is operating at the current time. Most of Ayala Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Ayala Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Ayala Pharmaceuticals' price. Additionally, you may evaluate how the addition of Ayala Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.